Trading Report: Today: 3,818 Shares of Quest Diagnostics Inc. (DGX) are sold by Huntington National Bank

Today: 3,818 Shares of Quest Diagnostics Inc. (DGX) are sold by Huntington National Bank

Huntington National Bank cut its position in Quest Diagnostics Inc. (NYSE:DGX) by 17.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,699 shares of the company’s stock after selling 3,818 shares during the period. Huntington National Bank’s holdings in Quest Diagnostics were worth $1,441,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Quest Diagnostics by 2.0% in the first quarter. Legal & General Group Plc now owns 716,279 shares of the company’s stock worth $51,184,000 after buying an additional 13,937 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in shares of Quest Diagnostics by 47.2% in the second quarter. Candriam Luxembourg S.C.A. now owns 217,486 shares of the company’s stock worth $17,706,000 after buying an additional 69,734 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Quest Diagnostics by 2.3% in the first quarter. Geode Capital Management LLC now owns 1,279,165 shares of the company’s stock worth $91,230,000 after buying an additional 28,485 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Quest Diagnostics by 3.9% in the first quarter. Lazard Asset Management LLC now owns 2,285 shares of the company’s stock worth $163,000 after buying an additional 86 shares in the last quarter. Finally, Investment House LLC raised its stake in shares of Quest Diagnostics by 2.7% in the second quarter. Investment House LLC now owns 2,978 shares of the company’s stock worth $242,000 after buying an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 91.32% of the company’s stock.

Quest Diagnostics Inc. (NYSE:DGX) traded down 0.18% during trading on Friday, hitting $83.17. 581,437 shares of the stock traded hands. Quest Diagnostics Inc. has a 52-week low of $59.66 and a 52-week high of $86.85. The stock has a 50 day moving average price of $83.67 and a 200-day moving average price of $80.16. The stock has a market cap of $11.56 billion, a P/E ratio of 14.51 and a beta of 0.70.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 21st. The company reported $1.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.02. The firm earned $1.91 billion during the quarter, compared to analyst estimates of $1.91 billion. Quest Diagnostics had a net margin of 11.02% and a return on equity of 14.41%. Quest Diagnostics’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the firm posted $1.25 EPS. On average, analysts anticipate that Quest Diagnostics Inc. will post $5.11 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 19th. Investors of record on Tuesday, October 4th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 1.92%. The ex-dividend date is Friday, September 30th. Quest Diagnostics’s payout ratio is currently 28.02%.

DGX has been the subject of a number of research analyst reports. Citigroup Inc. initiated coverage on shares of Quest Diagnostics in a research note on Friday, September 9th. They issued a “neutral” rating and a $86.00 price target for the company. Canaccord Genuity set a $90.00 price target on shares of Quest Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, September 14th. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $93.00 target price for the company in a research report on Wednesday, September 21st. Mizuho lowered shares of Quest Diagnostics from a “buy” rating to a “neutral” rating and boosted their target price for the company from $84.00 to $86.00 in a research report on Wednesday, August 31st. Finally, Jyske Bank lowered shares of Quest Diagnostics from a “neutral” rating to a “sell” rating in a research report on Friday, June 24th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $82.45.

In other Quest Diagnostics news, Director Jeffrey M. Leiden sold 6,345 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $85.62, for a total transaction of $543,258.90. Following the completion of the transaction, the director now directly owns 7,233 shares of the company’s stock, valued at approximately $619,289.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John B. Ziegler sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $84.36, for a total transaction of $84,360.00. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.

Related posts

Leave a Comment